238 related articles for article (PubMed ID: 17806042)
21. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
[TBL] [Abstract][Full Text] [Related]
22. Nosocomial bloodstream infections caused by Streptococcus pneumoniae.
Bouza E; Pintado V; Rivera S; Blázquez R; Muñoz P; Cercenado E; Loza E; Rodríguez-Créixems M; Moreno S;
Clin Microbiol Infect; 2005 Nov; 11(11):919-24. PubMed ID: 16216109
[TBL] [Abstract][Full Text] [Related]
23. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination.
Dworkin MS; Ward JW; Hanson DL; Jones JL; Kaplan JE;
Clin Infect Dis; 2001 Mar; 32(5):794-800. PubMed ID: 11229848
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
[TBL] [Abstract][Full Text] [Related]
25. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia.
Musher DM; Rueda-Jaimes AM; Graviss EA; Rodriguez-Barradas MC
Clin Infect Dis; 2006 Oct; 43(8):1004-8. PubMed ID: 16983612
[TBL] [Abstract][Full Text] [Related]
26. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
[TBL] [Abstract][Full Text] [Related]
27. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV.
Guiguet M; Furco A; Tattevin P; Costagliola D; Molina JM;
HIV Med; 2007 Mar; 8(2):124-30. PubMed ID: 17352769
[TBL] [Abstract][Full Text] [Related]
28. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults.
French N; Moore M; Haikala R; Kayhty H; Gilks CF
J Infect Dis; 2004 Aug; 190(4):707-12. PubMed ID: 15272398
[TBL] [Abstract][Full Text] [Related]
29. Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era.
Onwubiko C; Swiatlo E; McDaniel LS
J Clin Microbiol; 2008 Nov; 46(11):3621-5. PubMed ID: 18845823
[TBL] [Abstract][Full Text] [Related]
30. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.
Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N
J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
Mary-Krause M; Billaud E; Poizot-Martin I; Simon A; Dhiver C; Dupont C; Salmon D; Roudiere L; Costagliola D;
AIDS; 2006 Aug; 20(12):1627-35. PubMed ID: 16868444
[TBL] [Abstract][Full Text] [Related]
32. HIV and pneumococcal disease.
Klugman KP; Madhi SA; Feldman C
Curr Opin Infect Dis; 2007 Feb; 20(1):11-5. PubMed ID: 17197876
[TBL] [Abstract][Full Text] [Related]
33. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.
Madhi SA; Kuwanda L; Cutland C; Klugman KP
Clin Infect Dis; 2005 May; 40(10):1511-8. PubMed ID: 15844075
[TBL] [Abstract][Full Text] [Related]
34. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era.
Munier AL; de Lastours V; Porcher R; Donay JL; Pons JL; Molina JM
Int J STD AIDS; 2014 Dec; 25(14):1022-8. PubMed ID: 24676129
[TBL] [Abstract][Full Text] [Related]
36. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
[TBL] [Abstract][Full Text] [Related]
37. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy.
Jordano Q; Falcó V; Almirante B; Planes AM; del Valle O; Ribera E; Len O; Pigrau C; Pahissa A
Clin Infect Dis; 2004 Jun; 38(11):1623-8. PubMed ID: 15156452
[TBL] [Abstract][Full Text] [Related]
38. Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006.
Steenhoff AP; Wood SM; Rutstein RM; Wahl A; McGowan KL; Shah SS
Pediatr Infect Dis J; 2008 Oct; 27(10):886-91. PubMed ID: 18776825
[TBL] [Abstract][Full Text] [Related]
39. Pneumococcal vaccine failure in an HIV-infected patient with fatal pneumococcal sepsis and HCV-related cirrhosis.
Begemann M; Policar M
Mt Sinai J Med; 2001 Nov; 68(6):396-9. PubMed ID: 11687868
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
